Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy-Reference-Cited by-同舟云学术

Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy

Published:2021-11 Issue:11 Volume:2 Page:100247
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Bertin Lise,Canellas Anthony,Abbar Baptiste,Veyri Marianne,Spano Jean-Philippe,Cadranel Jacques,Lavolé Armelle

Funder

Merck Sharp and Dohme

AstraZeneca

Roche

Eli Lilly and Company

Pfizer

Gilead Sciences

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000;Morlat;AIDS,2014

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

4. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review;Cook;JAMA Oncol,2019

5. 1389P IFCT-1602 CHIVA2 phase II trial: nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC);Lavole;Ann Oncol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique;Revue des Maladies Respiratoires Actualités;2022-10